IFN-γ treatment amplified the expression of genes associated with signaling pathways that regulate lipid/obesity metabolism (RPTOR) [43]; vesicle trafficking (SEC23B) [44]; expansion of vesicles (ATG7, ATG10, and ATG16L2); and protection, maintenance, and adhesion of lysosomes (LAMP2) [44] in M. leprae-stimulated cultures. The gene discussed is ATG16L2; the disease is obesity disorder.